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osting by EAbstract The core objective of nanoparticles is to control and manipulate biomacromolecular con-
structs and supramolecular assemblies that are critical to living cells in order to improve the quality of
human health. By deﬁnition, these constructs and assemblies are nanoscale and include entities such as
drugs, proteins, DNA/RNA, viruses, cellular lipid bilayers, cellular receptor sites and antibody vari-
able regions critical for immunology and are involved in events of nanoscale proportions. The emer-
gence of such nanotherapeutics/diagnostics will allow a deeper understanding of human longevity and
human ills that include cancer, cardiovascular disease and genetic disorders. A technology platform
that provides a wide range of synthetic nanostructures that may be controlled as a function of size,
shape and surface chemistry and scale to these nanotechnical dimensions will be a critical ﬁrst step
in developing appropriate tools and a scientiﬁc basis for understanding nanoparticles.
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Conventional preparations like solution, suspension or emul-
sion suffer from certain limitations like high dose and low
availability, ﬁrst pass effect, intolerance, instability, and they
exhibit ﬂuctuations in plasma drug levels and do not provide
sustained effect, therefore there is a need for some novel carri-
ers which could meet ideal requirement of drug delivery sys-
tem. Recently nanoparticles delivery system has been
proposed as colloidal drug carriers. Nanoparticles (NP) are a
type of colloidal drug delivery system comprising particles with
a size range from 10 to 1000 nm in diameter. Nanoparticles
may or may not exhibit size-related properties that differ sig-
niﬁcantly from those observed in ﬁne particles or bulk materi-
als (Buzea et al., 2007). The key advantages of nanoparticles
are (1) improved bioavailability by enhancing aqueous solubil-
ity, (2) increasing resistance time in the body (increasing half
life for clearance/increasing speciﬁcity for its cognate receptors
and (3) targeting drug to speciﬁc location in the body (its site
of action). This results in concomitant reduction in quantity of
the drug required and dosage toxicity, enabling the safe deliv-
ery of toxic therapeutic drugs and protection of non target tis-
sues and cells from severe side effects (Irving, 2007). It is
increasingly used in different applications, including drug car-
rier systems and to pass organ barriers such as the blood-brain
barrier, cell membrane etc (Abhilash, 2010). They are based on
biocompatible lipid and provide sustained effect by either dif-
fusion or dissolution (Cavalli et al., 1995; Mu¨ller et al., 2000;
Yang et al., 1999; zur Mu¨hlen and Mehnert, 1998).
2. Drug release from nanoparticles
The nanoparticle is coated by polymer, which releases the drug
by controlled diffusion or erosion from the core across the
polymeric membrane or matrix. The membrane coating acts
as a barrier to release, therefore, the solubility and diffusivity
of drug in polymer membrane becomes the determining factor
in drug release. Furthermore release rate can also be affected
by ionic interaction between the drug and addition of auxillary
ingredients. When the drug is involved in interaction with aux-
illary ingredients to form a less water soluble complex, then the
drug release can be very slow with almost no burst release ef-
fect (Chen et al., 1994).
To develop a successful nanoparticulate system, both drug
release and polymer biodegradation are important consider-
ation factors. In general, drug release rate depends on (1) sol-ubility of drug, (2) desorption of the surface bound/ adsorbed
drug, (3) drug diffusion through the nanoparticle matrix, (4)
nanoparticle matrix erosion/degradation and (5) combination
of erosion/diffusion process (Mohanraj and Chen, 2006). Thus
solubility, diffusion and biodegradation of the matrix materi-
als govern the release process.
3. Types of nanoparticles
Extensive libraries of nanoparticles, composed of an assort-
ment of different sizes, shapes, and materials, and with various
chemical and surface properties, have already been con-
structed. The ﬁeld of nanotechnology is under constant and ra-
pid growth and new additions continue to supplement these
libraries. The classes of nanoparticles listed below are all very
general and multi-functional; however, some of their basic
properties and current known uses in nanomedicine are de-
scribed here.
3.1. Fullerenes
A fullerene is any molecule composed entirely of carbon, in the
form of a hollow sphere, ellipsoid, or tube. Spherical fullerenes
are also called buckyballs, and cylindrical ones are called car-
bon nanotubes or buckytubes. Fullerenes are similar in struc-
ture to the graphite, which is composed of stacked grapheme
sheets of linked hexagonal rings, additionally they may also
contain pentagonal (or sometimes heptagonal) rings to give
potentially porous molecules (Holister et al., 2003). Buckyball
clusters or buckyballs composed of less than 300 carbon atoms
are commonly known as endohedral fullerenes and include the
most common fullerene, buckminsterfullerene, C60. Megatubes
are larger in diameter than nanotubes and prepared with walls
of different thickness which is potentially used for the trans-
port of a variety of molecules of different sizes (Mitchell
et al., 2001). Nano ‘‘onions’’ are spherical particles based on
multiple carbon layers surrounding a buckyball core which
are proposed for lubricants (Sano et al., 2001). These proper-
ties of fullerenes hold great promise in health and personal care
application. The versatile biomedical applications are enlisted
in Table 1.
3.2. Solid lipid nanoparticles (SLNs)
SLNs mainly comprise lipids that are in solid phase at the
room temperature and surfactants for emulsiﬁcation, the mean
Table 1 Biomedical application of fullerenes.
Fullerenes composition Application References
Fullerene (C60) HIV proteases Friedman et al. (1993) and Sijbesma et al.
(1993)
Fulleropyrrolidines HIV-1 and HIV-2 Marchesan et al. (2005)
Dendrofullerene 1 HIV-1 replication Brettreich and Hirsch (1998) and Schuster
et al. (2000)
Amino acid derivatives of fullerene C60
(ADF)
HIV and human cytomegalovirus
replication
Kotelnikova et al. (2003)
Buckminsterfullerene Semliki forest virus (SFV, Togaviridae) or
vesicular stomatitis virus (VSV,
Rhabdoviridae
Kaesermann and Kempf (1997)
Cationic, anionic and amino acid type
fullerene
HIV-reverse transcriptase and hepatitis C
virus replication
Mashino et al. (2005)
Fullerene (C60) 34 methyl radicals Free radicals and oxidative stress Krusic et al. (1991)
Fullerene (C60) Liver toxicity and diminished lipid
peroxidation
Slater et al. (1985)
C3-Fullero-tris-methanodicarboxylic acid Apoptosis of neuronal cells Dugan et al. (1997)
Carboxyfullerene Apoptosis of hepatoma cells Huang et al. (1998)
Carboxyfullerenes Neurological disease including
Parkinson’s disease
Dugan et al. (1997)
Fullerene (C60) with organic cationic
compounds, viral carriers, recombinant
proteins and inorganic nanoparticles
Gene transfer Azzam and Domb (2004)
Metallofullerol Leukemia and bone cancer Thrash et al. (1999)
Nanoparticles: Emerging carriers for drug delivery 131diameters of which range from 50 nm to 1000 nm for colloid
drug delivery applications (zur Mu¨hlen et al., 1998). SLNs of-
fer unique properties such as small size, large surface area, high
drug loading, the interaction of phases at the interfaces, and
are attractive for their potential to improve performance of
pharmaceuticals, neutraceuticals and other materials (Cavalli
et al., 1993). The typical methods of preparing SLNs include
spray drying (Freitas and Mu¨ller, 1998), high shear mixing
(Domb, 1993), ultra-sonication (zur Mu¨hlen, 1996; Eldem
et al, 1991), and high pressure homogenization (HPH) (Mu¨ller
et al., 1996; Speiser, 1990). Solid lipids utilized in SLN formu-
lations include fatty acids (e.g. palmitic acid, decanoic acid,
and behenic acid), triglycerides (e.g. trilaurin, trimyristin,
and tripalmitin), steroids (e.g. cholesterol), partial glycerides
(e.g. glyceryl monostearate and gylceryl behenate) and waxes
(e.g. cetyl palmitate). Several types of surfactants are com-
monly used as emulsiﬁers to stabilize lipid dispersion, includ-
ing soybean lecithin, phosphatidylcholine, poloxamer 188,
sodium cholate, and sodium glycocholate (Zhang et al., 2010).
Advantages of these solid lipid nanoparticles (SLN) are the
use of physiological lipids, the avoidance of organic solvents in
the preparation process, and a wide potential application spec-
trum (dermal, oral, intravenous). Additionally, improved bio-
availability, protection of sensitive drug molecules from the
environment (water, light) and controlled and/or targeted drug
release (Mehnert and Ma¨der, 2001; Mu¨ller et al., 2002; Mu¨ller
et al., 2000), improved stability of pharmaceuticals, feasibilities
of carrying both lipophilic and hydrophilic drugs and most lip-
ids being biodegradable (Mu¨ller and Runge, 1998; Jenning
et al., 2000).
SLNs possess a better stability and ease of upgradability to
production scale as compared to liposomes. This property may
be very important for many modes of targeting. SLNs form the
basis of colloidal drug delivery systems, which are biodegrad-
able and capable of being stored for at least one year. Thereare several potential applications of SLNs some of which are
given in Table 2.
3.3. Liposomes
Liposomes are vesicular structures with an aqueous core sur-
rounded by a hydrophobic lipid bilayer, created by the extru-
sion of phospholipids. Phospholipids are GRAS (generally
recognised as safe) ingredients, therefore minimizing the po-
tential for adverse effects. Solutes, such as drugs, in the core
cannot pass through the hydrophobic bilayer however hydro-
phobic molecules can be absorbed into the bilayer, enabling
the liposome to carry both hydrophilic and hydrophobic mol-
ecules. The lipid bilayer of liposomes can fuse with other bilay-
ers such as the cell membrane, which promotes release of its
contents, making them useful for drug delivery and cosmetic
delivery applications. Liposomes that have vesicles in the range
of nanometers are also called nanoliposomes (Zhang and Gra-
nick, 2006; Cevc, 1996). Liposomes can vary in size, from
15 nm up to several lm and can have either a single layer (uni-
lamellar) or multiple phospholipid bilayer membranes (multi-
lamellar) structure. Unilamellar vesicles (ULVs) can be
further classiﬁed into small unilamellar vesicles (SUVs) and
large unilamellar vesicles (LUVs) depending on their size range
(Vemuri and Rhodes, 1995).
The unique structure of liposomes, a lipid membrane sur-
rounding an aqueous cavity, enables them to carry both hydro-
phobic and hydrophilic compounds without chemical
modiﬁcation. In addition, the liposome surface can be easily
functionalized with ‘stealth’ material to enhance their in vivo
stability or targeting ligands to enable preferential delivery of
liposomes. These versatile properties of liposomes made them
to be used as potent carrier for various drugs like antibacteri-
als, antivirals, insulin, antineoplastics and plasmid DNA
(Table 3).
Table 2 Biomedical application of solid lipid nanoparticles.
SLN composition Drug Application References
Stearic acid Rifampicin, isoniazid,
pyrazinamide
Mycobacterium
tuberculosis
Pandey and Khuller
(2005)
Stearic acid, soya
phosphatidylcholine, and
Sodium taurocholate
Ciproﬂoxacin
hydrochloride,
tobramycin
Gram-negative bacteria,
grampositive bacteria
and mycoplasma
Jain and Banerjee (2008)
Glyceryl tripalmitate and
tyloxapol
Clotrimazole Fungi (e.g. yeast,
aspergilli,
dermatophytes)
Souto et al. (2004)
Glyceryl behenate and sodium
deoxycholate
Ketoconazole Fungi Souto and Mu¨ller (2005)
Glyceryl behenate, propylene
glycol, tween 80, and Glyceryl
monostearate
Miconazole nitrate Fungi Bhalekar et al. (2009)
Glycerol palmitostearate Econazole nitrate Fungi Sanna et al. (2007)
Cetyl palmitate Insulin Type 1 diabetes Sarmento et al. (2007)
Lecithin, SODIUM taurocholate Nimesulide Inﬂammation Jain et al. (2009a,b)
Oleic acid Ibuprofen Inﬂammation Panga et al. (2009)
Poly(lactide) (PLA),
poly(lactideco-glycolide)
(PLGA), poly-e-caprolactone
(PCL) and poly(ortho esters)
Bacterial and viral
antigens
Immunity Tamber et al. (2005),
Storni et al. (2005) and
Yuki and Kiyono (2003)
Stearic acid, soya
phosphatidylcholine, and sodium
taurocholate
Tobramycin Pseudomonas aeruginosa Cavalli et al. (2002)
Soyabean-oil Doxorubicin Breast cancer Wong et al. (2006)
Hyaluronic acid–coupled
chitosan
Oxaliplatin Colorectal cancer Jain et al. (2009a,b)
Cholesteryl butyrate Doxorubicin, paclitaxel Colorectal cancer Serpe et al. (2004)
SLN Tamoxifen, Breast cancer Fontana et al. (2005)
SLN Methotrexate and
camptothecin
Carcinoma Ruckmani et al. (2006)
and Yang et al. (1999)
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Nanostructured Lipid Carriers are produced from blend of so-
lid and liquid lipids, but particles are in solid state at body tem-
perature. Lipids are versatile molecules that may form
differently structured solid matrices, such as the nanostruc-
tured lipid carriers (NLC) and the lipid drug conjugate nano-
particles (LDC), that have been created to improve drug
loading capacity (Wissing et al., 2004). The NLC production
is based on solidiﬁed emulsion (dispersed phase) technologies.
NLC can present an insufﬁcient loading capacity due to drug
expulsion after polymorphic transition during storage, partic-
ularly if the lipid matrix consists of similar molecules.
Drug release from lipid particles occurs by diffusion and
simultaneously by lipid particle degradation in the body. In
some cases it might be desirable to have a controlled fast re-
lease going beyond diffusion and degradation. Ideally this re-
lease should be triggered by an impulse when the particles
are administered. NLCs accommodate the drug because of
their highly unordered lipid structures. A desired burst drug re-
lease can be initiated by applying the trigger impulse to the ma-
trix to convert in a more ordered structure. NLCs of certain
structures can be triggered this way (Radtke and Mu¨ller,
2001). NLCs can generally be applied where solid nanoparti-
cles possess advantages for the delivery of drugs. Major appli-
cation areas in pharmaceutics are topical drug delivery, oral
and parenteral (subcutaneous or intramuscular and intrave-nous) route. LDC nanoparticles have proved particularly use-
ful for targeting water-soluble drug administration. They also
have applications in cosmetics, food and agricultural products.
These have been utilized in the delivery of anti-inﬂammatory
compounds, cosmetic preparation, topical cortico therapy
and also increases bioavailability and drug loading capacity.
Few biomedical applications of NLCs are enlisted in Table 4.
3.5. Nanoshells
Nanoshells are also notorious as core-shells, nanoshells are
spherical cores of a particular compound (concentric particles)
surrounded by a shell or outer coating of thin layer of another
material, which is a few 1–20 nm nanometers thick (Liz-Mar-
zan et al., 2001; Davies et al., 1998; Templeton et al., 2000;
Xia et al., 2000). Nanoshell particles are highly functional
materials show modiﬁed and improved properties than their
single component counterparts or nanoparticles of the same
size. Their properties can be modiﬁed by changing either the
constituting materials or core-to-shell ratio (Oldenberg et al.,
1998). Nanoshell materials can be synthesized from semicon-
ductors (dielectric materials such as silica and polystyrene),
metals and insulators. Usually dielectric materials such as silica
and polystyrene are commonly used as core because they are
highly stable (Kalele et al., 2006a,b).
Metal nanoshells are a novel type of composite spherical
nanoparticles consisting of a dielectric core covered by a thin
Table 3 Biomedical application of liposomes.
Liposome composition Drug Application References
Hydrogenated soya, phosphatidylcholine,
cholesterol and distearoylphosphatidylglycerol
(DSPG)
Amphotericin B Aspergillus fumigatus Takemoto et al. (2004)
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine
(DPPC) and cholesterol
Polymyxin B Pseudomonas aeruginosa Omri et al. (2002)
Hydrogenated Soya phosphatidylcholine (PC)
and cholesterol
Ampillicin Micrococcus luteus and
Salmonella typhimurium
Schumacher and Margalit (1997)
Dipalmitoyl-phosphatidylcholine, dipalmitoyl-
phosphatidylglycerol and cholesterol
Ciproﬂoxacin Salmonella dublin Magallanes et al. (1993)
Dipalmitoyl-phosphatidylcholine (DPPC),
cholesterol and dimethylammonium ethane
carbamoyl cholesterol (DC-chol)
Benzyl penicillin Staphylococcus aureus Kim and Jones (2004)
Phosphatidylcholine, cholesterol and
phosphatidylinositol
Netilmicin Bacillus subtilis and
Escherichia coli
Mimoso et al. (1997)
Partially hydrogenated egg phosphatidylcholine
(PHEPC), cholesterol and 1,2-distearoylsn-
glycero-3-phosphoethanolamine-N-(polyethylene
glycol-2000) (PEGDSPE)
Gentamicin Klebsiella pneumoniae Schiﬀelers et al. (2001)
Phosphatidyl glycerol, phosphatidyl choline and
cholesterol
Streptomycin Mycobacterium avium Gangadharam et al. (1991)
Hydrogenated soy phosphatidylcholine,
cholesterol and distearoylphosphatidylglycerol
(DSPG)
Amikacin Gram-negative bacteria Fielding et al. (1998)
Stearylamine (SA) and dicetyl phosphate Zidovudine Human immunodeﬁciency
virus
Kaur et al. (2008)
Egg phosphatidylcholine, diacetylphosphate and
cholesterol
Vancomycin or teicoplanin methicillin-resistant
Staphylococcus aureus
(MRSA)
Onyeji et al. (1994)
DC-Chol liposome Plasmid DNA Gene transfer in
subcutaneous tumor
Whitemore et al. (2001)
Liposome Daunorubicin and
doxorubicin
Breast cancer Park (2002)
Liposome Anti-GD2
immunoliposomes,
Liposomes Entrapping
Fenretinide (HPR), Gold-
Containing Liposomes
Neuroblastoma Di Paolo et al. (2009)
Hepatically targeted liposomes Insulin Diabetes mellitus Spangler (1990)
Nanoparticles: Emerging carriers for drug delivery 133metallic shell which is typically gold. Nanoshells possess highly
favorable optical and chemical properties for biomedical imag-
ing and therapeutic applications. Nanoshells offer other
advantages over conventional organic dyes including improved
optical properties and reduced susceptibility to chemical/ther-
mal denaturation. Furthermore, the same conjugation proto-
cols used to bind biomolecules to gold colloid are easily
modiﬁed for nanoshells (Loo et al., 2004). When a nanoshell
and polymer matrix is illuminated with resonant wavelength,
nanoshells absorb heat and transfer to the local environment.
This causes collapse of the network and release of the drug. In
core shell particles-based drug delivery systems either the drug
can be encapsulated or adsorbed onto the shell surface
(Sparnacci et al., 2002). The shell interacts with the drug via
a speciﬁc functional group or by electrostatic stabilization
method. When it comes in contact with the biological system,
it directs the drug. In imaging applications, nanoshells can be
tagged with speciﬁc antibodies for diseased tissues or tumors.
Nanoshell materials have received considerable attention in
recent years because of potential applications associated with
them. A few applications in the area of imaging and diagnos-
tics are discussed in Table 5.3.6. Quantum dots (QD)
The quantum dots are semiconductor nanocrystals and core-
shell nanocrystals containing interface between different
semiconductor materials. The size of quantum dots can be con-
tinuously tuned from 2 to 10 nm, which, after polymer encap-
sulation, generally increases to 5–20 nm in diameter. Particles
smaller than 5 nm are quickly cleared by renal ﬁltration (Choi
et al., 2007a,b). Semiconductor nanocrystals have unique and
fascinating optical properties, become an indispensable tool
in biomedical research, especially for multiplexed, quantitative
and long-term ﬂuorescence imaging and detection (Michalet
et al., 2005; Medintz et al., 2005; Alivisatos, 2004; Smith
et al., 2006). QD core can serve as the structural scaffold, and
the imaging contrast agent and small molecule hydrophobic
drugs can be embedded between the inorganic core and the
amphiphilic polymer coating layer. Hydrophilic therapeutic
agents including small interfering RNA (siRNA) and antisense
oligodeoxynucleotide (ODN)) and targeting biomolecules such
as antibodies, peptides and aptamers can be immobilized onto
the hydrophilic side of the amphiphilic polymer via either cova-
lent or non-covalent bonds. This fully integrated nanostructure
Table 4 Biomedical application of nonstructured lipid carriers (NLC).
Nanostructured lipid carrier’s composition Application References
Phosphatidylcholine, dynasan and ﬂurbiprofen Sustained release of anti-
inﬂammatory drug
Bhaskar et al. (2009)
Stearic acid, oleic acid, carbapol and minoxidil Pharmaceutical, cosmetic and
biochemical purposes
Silva et al. (2009)
Fluticasone propionate, glyceryl palmito-stearate
and PEG
Topical corticotherapy Doktorovova´ et al. (2010)
Beta-carotene loaded Propylene glycol
monostearate
Evaluate the feasibility Hentschel et al. (2008)
Monostearin and caprylic and capric triglycerides Improved drug loading capacity
and controled release properties
Hu et al. (2006)
Clozapine, triglycerides (trimyristin, tripalmitin
and tristearin), soylecithin 95% and poloxamer
188)
Improved bioavailability Venkateswarlu and Manjunath (2004)
Table 5 Biomedical application of nanoshells.
Nanoshell’s composition Applications References
Silica coating of silver colloids Stability of colloids Ung et al. (1998)
Gold nanoshell Detection of DNA Thaxton et al. (2005)
Gold nanoshell Immunoassay to detect analytes Hirsch et al. (2003a)
Nanoshell To detect cancer cells Loo et al. (2004)
Nanoshell To detect tumors Hirsch et al. (2003b)
Silica-silver core-shell particles To detect antibodies Kalele et al. (2005)
Silver nanoshell To detect microorganisms Kalele et al. (2006b)
Silver nanoshells Detection of toxic ions such as Cd, Hg and Pb present in water Kalele et al. (2006a)
Gold nanoshells particles
conjugated with enzymes and
antibodies embedded in the
polymer like
Nisopropylacrylamide and
acrylamide
Imaging of the diseases Sparnacci et al. (2002)
134 S.R. Mudshinge et al.may behave like magic bullets that will not only identify, but
bind to diseased cells and treat it. It will also emit detectable sig-
nals for real-time monitoring of its trajectory (Qi and Gao,
2008). These beneﬁts enable applications of QDs in medical
imaging and disease detection (Table 6).
3.7. Superparamagnetic nanoparticles
Superparamagnetic molecules are those that are attracted to a
magnetic ﬁeld but do not retain residual magnetism after the
ﬁeld is removed. Nanoparticles of iron oxide with diameters
in the 5–100 nm range have been used for selective magnetic
bioseparations. Typical techniques involve coating the parti-
cles with antibodies to cell-speciﬁc antigens, for separation
from the surrounding matrix.
The main advantages of superparamagnetic nanoparticles
are that they can be visualized in magnetic resonance imaging
(MRI) due to their paramagnetic properties; they can be
guided to a location by the use of magnetic ﬁeld and heated
by magnetic ﬁeld to trigger the drug release (Irving, 2007).
Superparamagnetic nanoparticles belong to the class of
inorganic based particles having an iron oxide core coated
by either inorganic materials (silica, gold) and organic (phos-
pholipids, fatty acids, polysaccharides, peptides or other sur-
factants and polymers) (Gupta and Curtis, 2004; Babic et al.,2008; Euliss et al., 2003). In contrast to other nanoparticles,
superparamagnetic nanoparticles based on their inducible
magnetization, their magnetic properties allow them to be di-
rected to a deﬁned location or heated in the presence of an
externally applied AC magnetic ﬁeld. These characteristics
make them attractive for many applications, ranging from var-
ious separation techniques and contrast enhancing agents for
MRI to drug delivery systems, magnetic hyperthermia (local
heat source in the case of tumor therapy), and magnetically as-
sisted transfection of cells (Hora´k, 2005; Gupta and Gupta,
2005; Jordan et al., 2001; Neuberger et al., 2005).
Already marketable products, so-called beads, are micron
sized polymer particles loaded with SPIONs. Such beads can
be functionalized with molecules that allow a speciﬁc adsorp-
tion of proteins or other biomolecules and subsequent separa-
tion in a magnetic ﬁeld gradient for diagnostic purposes. More
interesting applications, like imaging of single cells or tumors,
delivery of drugs or genes, local heating and separation of pep-
tides, signaling molecules or organelles from a single living cell
or from a living (human) body are still subjects of intensive re-
search. The transdisciplinarity of basic and translational re-
search carried out in superparamagnetic nanoparticles during
the last decades lead to a broad ﬁeld of novel applications
for superparamagnetic nanoparticles. There are several
potential applications of superparamagnetic nanoparticles
Table 6 Biomedical application of quantum dots.
Quantum dot’s composition Applications References
Quantum dots For measuring protein conformational
changes, monitoring protein interactions,
assaying of enzyme activity, in Fluorescence
resonance energy transfer (FRET)
technologies, particularly when conjugated to
biological molecules, including antibodies, for
use in immunoassays
Heyduk (2002), Day et al. (2001), Li and Bugg
(2004), Kagan et al. (1996), Willard et al.
(2001), Wang et al. (2002) Hohng and Ha
(2005)
QD-conjugated oligonucleotide
sequences (attached via surface
carboxylic acid groups)
Gene technology Pathak et al. (2001) and Gerion et al. (2002)
Conjugation of quantum dot with
Tat protein, and by encapsulation in
cholesterol-bearing pullulan (CHP)
modiﬁed with amine groups coating
with a silica shell
Fluorescent labeling of cellular proteins and
diﬀerent intracellular structures
Hasegawa et al. (2005) and Derfus et al.
(2004)
QDs encapsulated in phospholipid
micelles
Cell tracking and color imaging of live cells Dubertret et al. (2002) and Jaiswal et al.
(2003)
Transferrin-bound QDs, wheat germ
agglutinin and transferrin-bound
QDs,p53 conjugated with QDs
Pathogen and toxin detection such as
Cryptosporidium parvum and Giardia lamblia,
Escherichia coli 0157:H7 and Salmonella
typhi, Hepatitis B and C viruses and Listeria
monocytogenes
Lee et al. (2004), Zhu et al. (2004), Yang and
Li (2006), Gerion et al. (2003), Agrawal et al.
(2005), Goldman et al. (2002)
PEG-encapsulated QDs In vivo animal imaging, Lymph node
mapping
Gao et al. (2004), Jakub et al. (2003), Lim
et al. (2003)
Quantum dots Barriers to use in vivo Akerman et al. (2002)
Combination of QD imaging with
second-harmonic generation (SHG),
CdTe bound QDs
Tumor biology investigation, Cell motility
and metastatic potential, measurement of
diﬀerent cancer antigens
Choi et al. (2007), Parak et al. (2002),
Ghazani et al. (2006), Williams et al. (2001)
Table 7 Biomedical application of superparamagnetic nanoparticles.
Superparamagnetic nanoparticle’s composition Applications References
SPIONs coated with organic molecules showing an
overall median diameter of less than 50–160 nm
MRI contrast agents for
detecting liver tumors
Smith et al. (2007)
Superparamagnetic iron oxide nanoparticles Identify dangerous
arteriosclerotic plaques by MRI
Zur Mu¨hlen et al. (2007) and
Smith et al. (2007)
Superparamagnetic Iron oxide nanoparticles
(SPIONs) coated with polyvinylbenzyl-O-b-D-
galactopyranosyl-D-gluconamide (PVLA) with
galactose moieties
Liver-targeting MRI contrast
agent
Yoo et al. (2007)
Superparamagnetic iron oxide nanoparticles
conjugated to luteinizing hormone releasing hormone
(LHRH–SPIONs),
Enhanced MRI contrast in breast
cancer xenografts and metastases
in the lungs
Meng et al. (2009)
Superparamagnetic iron oxide nanoparticles Magnetic particle imaging Minard (2009)
Combidex a ultrasmall superparamagnetic iron oxide
(USPIO) covered covered dextran
Molecular imaging agent during
contrast-enhanced MRI
McIlwain (2008)
Monocrystalline iron oxide nanoparticles-47 [MION-
47]
Measures macrophage burden in
atherosclerosis
Morishige et al. (2010)
Colloidal dispersions of superparamagnetic
(subdomain) iron oxide nanoparticles
Magnetic ﬂuid hyperthermia
(MFH) in cancer treatment
Jordan et al. (1999)
Nanosized superparamagnetic nanoparticles (Fe3O4)
coated with the multivalent cationic agent,
polyethylenimine (PEI)
Puriﬁcation of plasmid DNA
from bacterial cells
Chiang et al. (2005)
Nanoparticles: Emerging carriers for drug delivery 135some of which are given in Table 7. The following issues are
not yet fully understood such as (1) the mechanisms utilized
by cells to take up multifunctional SPIONs in human cells in
culture, (2) are there membrane molecules involved?, (3) spe-ciﬁc adsorption of SPIONs to targeted subcellular components
after uptake, transport of drugs, plasmids or other substances
to speciﬁc cells followed by controlled release, (4) separation of
SPIONs from the cells after cell-uptake and speciﬁc adsorption
Table 8 Biomedical application of dendrimers.
Dendrimers composition Drug Application References
PAMAM (polyamidoamine) Chelated gadolinium Diagnose certain disorders of the
heart, brain and blood vessels
Wiener et al. (1994)
Poly(L-glutamic acid),
polyamidoamine and
poly(ethyleneimine)
Folic acid Breast cancer Wiener et al. (1997) and
Kukowska-Latallo et al. (2005)
PAMAM Antibodies speciﬁc to CD14 and
PSMA
Cell binding and internalization Thomas et al. (2004)
PAMAM Sulfamethoxazole Strep throat (Streptococcus),
staph infection (Staphylococcus
aureus), and ﬂu (Haemophilus
inﬂuenza)
Ma et al. (2007) and Abeylath
et al. (2008)
PAMAM (polyamidoamine) Nadiﬂoxacin, pruliﬂoxacin, Various bacteria Cheng et al. (2007b)
PAMAM (Polyamidoamine) PPI
(polypropyleneimine generation)
Nystatin and Terbinaﬁne Antifungal against Candida
albicans, Aspergillus niger and
Sachromyces cerevasae
Khairnar et al. (2010)
PAMAM (polyamidoamine) Propranolol Hypertension D’Emanuele et al. (2004)
Polyamidoamine (PAMAM)
dendrimers
Niclosmide Tapeworm Devarakonda et al. (2005)
Pegylated lysine based copolymeric
dendrimer
Artemether Plasmodium falciparum Bhadra et al. (2005)
PAMAM dendrimers with carboxylic
or hydroxyl surface groups
Pilocarpine Glaucoma Vandamme and Brobeck (2005)
and Tolia et al. (2008)
PAMAM Enoxaparin Pulmonary embolism Bai et al. (2007)
PAMAM Ketoprofen, Diﬂunisal Inﬂammation Cheng et al. (2007a)
PAMAM Indomethacin Inﬂammation Chauhan et al. (2003)
Polylysine dendrimer VivaGel (SPL7013 Gel) HIV, HSV and sexually
transmitted infections
Rupp et al. (2007)
Dendrimer High resolution X-ray image Diagnostic tool for
arteriosclerotic vasculature,
tumors, infarcts, kidneys or
eﬀerent urinary
Schumann et al. (2003)
Dendrimer Gene transfer of cytokine genes
(tumor necrosis factor,
interleukin-2, granulocyte-
macrophage colony-stimulating
factor)
Induce a systemic antitumor
immune response against residual
tumor cells
Culver (1994)
PAMAM 5-Fluorouracil Tumor Zhuo et al. (1999)
Dendrimer Isotope of boron (10B) Cancer Hawthorne (1993)
136 S.R. Mudshinge et al.to sub cellular components or to biomolecules like proteins
without interfering with cell function, (5) prevention of uncon-
trolled agglomeration of modiﬁed SPIONs in physiological liq-
uids, (6) short and long-term impact on cell functions by
loading cells of different phenotypes with such nanoparticles
(Hofmann-Amtenbrink et al., 2009).
3.8. Dendrimers
Dendrimers are unimolecular, monodisperse, micellar nano-
structures, around 20 nm in size, with a well-deﬁned, regularly
branched symmetrical structure and a high density of func-
tional end groups at their periphery. The structure of dendri-
mers consists of three distinct architectural regions as a focal
moiety or a core, layers of branched repeat units emerging
from the core, and functional end groups on the outer layer
of repeat units. They are known to be robust, covalently ﬁxed,
three dimensional structures possessing both a solvent-ﬁlled
interior core (nanoscale container) as well as a homogenous,
mathematically deﬁned, exterior surface functionality
(Grayson and Frechet, 2001; Svenson and Tomalia, 2005).Dendrimers are generally prepared using either a divergent
method or a convergent one (Hodge, 1993) with an architec-
ture like a tree branching out from a central point.
Dendrimeric vectors are most commonly used as parenteral
injections, either directly into the tumor tissue or intravenously
for systemic delivery (Tomalia et al. 2007). Dendrimers used in
drug delivery studies typically incorporate one or more of the
following polymers: polyamidoamine (PAMAM), melamine,
poly L-glutamic acid (PG), polyethyleneimine (PEI), polyprop-
yleneimine (PPI), and polyethylene glycol (PEG), Chitin. Den-
drimers may be used in two major modalities for targeting
vectors for diagnostic imaging, drug delivery, gene transfection
also detection and therapeutic treatment of cancer and other
diseases, namely by (1) passive targeting-nanodimension
mediated via EPR (enhanced permeability retention) effect
(Matsumura and Maeda, 1986) involving primary tumor vas-
cularization or organ-speciﬁc targeting (Kobayashi and
Brechbiel, 2003) and (2) active targeting-receptor-mediated
cell-speciﬁc targeting involving receptor-speciﬁc targeting
groups (Hofmann-Amtenbrink et al., 2009). There are several
potential applications of dendrimers in the ﬁeld of imaging,
Nanoparticles: Emerging carriers for drug delivery 137drug delivery, gene transfection and non-viral gene transfer.
Few applications are enrolled in Table 8.
4. Conclusion
There is a wide range of nanoparticulate materials and struc-
tures being developed for the delivery of therapeutic com-
pounds. Each has its own particular advantages, but as these
nanoparticles become optimized for their speciﬁc application,
the outcome will be better-controlled therapy as a result of tar-
geted delivery of smaller amounts of effective drugs to the re-
quired sites in the body. This is being made possible through
the use of advanced material, improved control of particle size,
and better understanding of interface between the biological
and material surfaces, and their effects in vivo. Some nanopar-
ticle based products are already approved by the US FDA,
several others are currently under development and clinical
assessment.Acknowledgements
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